Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Healthcare — Equipment & Devices.”
₹107 Cr revenue.
COGS 71.0%, employees 8.8%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.7%▲ | 12.3% |
| ROCE | 14.5%▼ | 15.3% |
| Net Margin | 7.2%▼ | 8.5% |
| EBITDA Margin | 12.6%▼ | 14.9% |
| Debt To Equity | 0.49x▲ | 0.10x |
Historical valuation data not available.
| (₹ Cr) | FY2025 |
|---|---|
| Revenue | ₹107 Cr |
| Other Income | ₹5 Cr |
| Total Income | ₹112 Cr |
| COGS | ₹76 Cr |
| ₹101 Cr | |
| Profit Before Tax | ₹10 Cr |
| ₹2 Cr | |
| Net Profit | ₹8 Cr |
| Profit (Owners) | ₹8 Cr |
| EPS | ₹7.70 |
| Diluted Shares | ₹1 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Please find enclosed Press Release being issued by the Company titled "Hemant Surgical Strengthens Healthcare Portfolio through Strategic Acquisition of Majority Stake in Lifesenz Cancer .... Please f...
With reference to intimation dated May 27, 2026, the Company has completed the acqusition of Lifesenz Cancer Labs Private Limited and has become subsidiary of the Company w.e.f. June 01, 2026.
Non-Applicability of Annual Secretarial Compliance Report for the Financial Year Ended March 31, 2026
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Singularity Equity Fund I
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Singularity Large Value Fund III
The Board of Directors at its meeting held today have approved Audited Financial Results of the Company for half and financial year ended March 31, 2026
Intimation of Closure of Trading Window
Intimation of receipt of purchase order from Central Medical Services Society, Ministry of Health and Family Welfare (Government of India).
Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018.
Statement of Deviation or Variation for half year ended on September 30, 2025
Statement of Deviation or Variation for the half year ended on September 30, 2025.
Unaudited financial results of the Company for the half year ended on September 30, 2025.
Outcome of Board Meeting held on Wednesday, November 12, 2025, pursuant to Regulations 30, 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) .... Outcom...
Hemant Surgical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve unaudited financial .... Hemant...
Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2025.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
No dividend history available for this company.